The use of proteolysis-resistant GLP-1 analogs (exendin-4, liraglutide, etc.) to improve feeding behavior, glycemic control and insulin sensitivity, and to prevent neurodegenerative changes in patients with T2DM and in experimental models of metabolic disorders [333–335,342,343,345,346]. Here, INS is linked to Other metabolic disease.